Command Palette

Search for a command to run...

Clinical Trials · NCT06003465

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

CompletedPhase 1Retatrutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
57
Start date
Aug 2023
Locations
3 sites, United States
Primary endpoint
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943
View Retatrutide compound reference